PF 3526299Alternative Names: PF-03526299; PF-3526299
Latest Information Update: 01 Jun 2011
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 27 Sep 2010 Phase-I development is ongoing
- 28 Feb 2008 Phase-I clinical trials in Asthma in USA (Inhalation)